CN114144427A - 用于检测和分离nmdar自身抗体的nmda受体构建体 - Google Patents

用于检测和分离nmdar自身抗体的nmda受体构建体 Download PDF

Info

Publication number
CN114144427A
CN114144427A CN202080051571.1A CN202080051571A CN114144427A CN 114144427 A CN114144427 A CN 114144427A CN 202080051571 A CN202080051571 A CN 202080051571A CN 114144427 A CN114144427 A CN 114144427A
Authority
CN
China
Prior art keywords
ser
leu
val
ile
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080051571.1A
Other languages
English (en)
Chinese (zh)
Inventor
汉斯-克里斯蒂安·科尔瑙
哈拉尔德·普吕斯
克雷格·柯蒂斯·加尔内
塔尼塔·弗雷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
German Neurodegenerative Disease Center
Original Assignee
German Neurodegenerative Disease Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by German Neurodegenerative Disease Center filed Critical German Neurodegenerative Disease Center
Publication of CN114144427A publication Critical patent/CN114144427A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70571—Assays involving receptors, cell surface antigens or cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7095—Inflammation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Peptides Or Proteins (AREA)
  • External Artificial Organs (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080051571.1A 2019-07-16 2020-07-02 用于检测和分离nmdar自身抗体的nmda受体构建体 Pending CN114144427A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP19186524.5 2019-07-16
EP19186524 2019-07-16
LU101308 2019-07-18
LULU101308 2019-07-18
PCT/EP2020/068732 WO2021008890A1 (en) 2019-07-16 2020-07-02 Nmda receptor constructs to detect and isolate nmdar autoantibodies

Publications (1)

Publication Number Publication Date
CN114144427A true CN114144427A (zh) 2022-03-04

Family

ID=71143759

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080051571.1A Pending CN114144427A (zh) 2019-07-16 2020-07-02 用于检测和分离nmdar自身抗体的nmda受体构建体

Country Status (6)

Country Link
US (1) US20230280340A1 (https=)
EP (1) EP3999850A1 (https=)
JP (2) JP7659905B2 (https=)
CN (1) CN114144427A (https=)
CA (1) CA3144900A1 (https=)
WO (1) WO2021008890A1 (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114891091A (zh) * 2022-06-13 2022-08-12 四川携光生物技术有限公司 一种抗nmdar脑炎重组抗原及应用
CN114957446A (zh) * 2022-05-31 2022-08-30 陕西脉元生物科技有限公司 与nmdar脑炎患者中的自身抗体结合的nmdar突变体及其构建方法
CN116253790A (zh) * 2022-12-13 2023-06-13 迪亚莱博（张家港）生物科技有限公司 一种用于抗nmdar抗体检测的nmdar重组蛋白及其制备方法及其应用
CN116440950A (zh) * 2023-02-24 2023-07-18 华东理工大学 一种催化剂及其制备方法和应用
CN118566499A (zh) * 2024-08-02 2024-08-30 成都海默云因医学检验实验室有限公司 一种GluN1和GluN2B亚基融合表达检测抗NMDAR抗体的CBA方法及检测试剂

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3999850A1 (en) * 2019-07-16 2022-05-25 Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) Nmda receptor constructs to detect and isolate nmdar autoantibodies
WO2021241616A1 (ja) 2020-05-27 2021-12-02 アステラス製薬株式会社 抗ヒトｎｒ１抗体誘導体
JPWO2024075803A1 (https=) * 2022-10-06 2024-04-11
AU2024242885A1 (en) * 2023-03-30 2025-09-11 Arialys Therapeutics, Inc. Detection of autoantibodies against nr1
AU2024315618A1 (en) * 2023-08-01 2026-01-22 Merida Biosciences, Inc. Molecules for controlling autoimmune response
CN118937669B (zh) * 2024-10-11 2025-02-18 杭州臻源生物医药科技有限公司 双色荧光检测抗nmdar抗体用固定试剂、方法及应用
CN120721960B (zh) * 2025-08-19 2025-11-21 上海金域医学检验所有限公司 一种自身免疫性脑炎抗体检测指示试剂、试剂盒与制备工艺

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030096331A1 (en) * 2001-06-27 2003-05-22 Dambinova Svetlana A. Rapid multiple panel of biomarkers in laboratory blood tests for TIA/stroke
CN101606062A (zh) * 2006-08-15 2009-12-16 宾夕法尼亚大学理事会 用于治疗和诊断自身免疫性脑炎或癫痫的方法和组合物
WO2012076000A2 (de) * 2010-12-06 2012-06-14 Euroimmun Medizinische Labordiagnostika Ag Verfahren zum nachweis von anti-nmda-rezeptor autoantikörpern zum einsatz in diagnoseverfahren

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770460B1 (en) * 1998-01-29 2004-08-03 Wallac Oy Fusion protein and its use in an immunoassay for the simultaneous detection of autoantibodies related to insulin-dependent diabetes mellitus
DE19818790A1 (de) 1998-04-27 1999-10-28 Affina Immuntechnik Gmbh Immunadsorptionsmatrix, Verfahren zu ihrer Herstellung und ihre Verwendung
AU2002220577A1 (en) 2000-09-28 2002-04-08 Affina Immuntechnik Gmbh Circulatory device for separating substances in bodily fluids, especially blood,and the use of said device
EP2035452B1 (en) * 2006-06-22 2012-04-25 Novo Nordisk A/S Soluble heterodimeric receptors and uses thereof
WO2013041029A1 (en) * 2011-09-23 2013-03-28 Igenimed Pharmaceuticals Inc. Novel soluble ctla4 variants
KR20160135749A (ko) * 2014-03-18 2016-11-28 샌포드 헬스 유방암 검출용 시약 및 검출 방법
GB201409234D0 (en) * 2014-05-23 2014-07-09 Isis Innovation Method
EP3999850A1 (en) * 2019-07-16 2022-05-25 Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) Nmda receptor constructs to detect and isolate nmdar autoantibodies

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030096331A1 (en) * 2001-06-27 2003-05-22 Dambinova Svetlana A. Rapid multiple panel of biomarkers in laboratory blood tests for TIA/stroke
CN101606062A (zh) * 2006-08-15 2009-12-16 宾夕法尼亚大学理事会 用于治疗和诊断自身免疫性脑炎或癫痫的方法和组合物
WO2012076000A2 (de) * 2010-12-06 2012-06-14 Euroimmun Medizinische Labordiagnostika Ag Verfahren zum nachweis von anti-nmda-rezeptor autoantikörpern zum einsatz in diagnoseverfahren

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JULIE JÉZÉQUEL 等: "Cell- and Single Molecule-Based Methods to Detect Anti-N-Methyl-D-Aspartate Receptor Autoantibodies in Patients With First-Episode Psychosis From the OPTiMiSE Project", BIOLOGICAL PSYCHIATRY, vol. 10, no. 82, pages 766 - 772 *
包玎等: "NMDAR1蛋白膜外抗原结构域的重组表达、纯化和免疫反应原性鉴定", 生物工程学报, vol. 33, no. 12, pages 1979 - 1988 *
邓波等: "2016AAN：NMDAR抗体在自身免疫性脑炎中发挥重要作用", pages 1 - 2, Retrieved from the Internet <URL:https://neuro.dxy.cn/article/490879> *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114957446A (zh) * 2022-05-31 2022-08-30 陕西脉元生物科技有限公司 与nmdar脑炎患者中的自身抗体结合的nmdar突变体及其构建方法
CN114957446B (zh) * 2022-05-31 2023-09-15 陕西脉元生物科技有限公司 与nmdar脑炎患者中的自身抗体结合的nmdar突变体及其构建方法
CN114891091A (zh) * 2022-06-13 2022-08-12 四川携光生物技术有限公司 一种抗nmdar脑炎重组抗原及应用
CN114891091B (zh) * 2022-06-13 2024-04-26 四川携光生物技术有限公司 一种抗nmdar脑炎重组抗原及应用
CN116253790A (zh) * 2022-12-13 2023-06-13 迪亚莱博（张家港）生物科技有限公司 一种用于抗nmdar抗体检测的nmdar重组蛋白及其制备方法及其应用
CN116440950A (zh) * 2023-02-24 2023-07-18 华东理工大学 一种催化剂及其制备方法和应用
CN116440950B (zh) * 2023-02-24 2023-09-12 华东理工大学 一种催化剂及其制备方法和应用
CN118566499A (zh) * 2024-08-02 2024-08-30 成都海默云因医学检验实验室有限公司 一种GluN1和GluN2B亚基融合表达检测抗NMDAR抗体的CBA方法及检测试剂
CN118566499B (zh) * 2024-08-02 2024-10-08 成都海默云因医学检验实验室有限公司 一种GluN1和GluN2B亚基融合表达检测抗NMDAR抗体的CBA方法及检测试剂

Also Published As

Publication number Publication date
JP7659905B2 (ja) 2025-04-10
EP3999850A1 (en) 2022-05-25
US20230280340A1 (en) 2023-09-07
JP2025094198A (ja) 2025-06-24
JP2022540913A (ja) 2022-09-20
CA3144900A1 (en) 2021-01-21
WO2021008890A1 (en) 2021-01-21

Similar Documents

Publication Publication Date Title
CN114144427A (zh) 用于检测和分离nmdar自身抗体的nmda受体构建体
JP6168364B2 (ja) リン酸化タウ凝集体に対する抗体
Katahira et al. Molecular cloning and functional characterization of the receptor for Clostridium perfringens enterotoxin
Hu et al. Molecular and functional characterization of the p62 complex, an assembly of nuclear pore complex glycoproteins.
CN114539411B (zh) 一种ror1抗体或其抗原结合片段
WO2003026493A2 (en) Diagnosis and treatment of diseases caused by mutations in cd72
JP2002536966A (ja) カルシウムチャネルファミリーの特徴付け
CN101821623A (zh) 用于精子性别选择的材料和方法
AU2007309516B2 (en) Human salty taste receptor and methods of modulating salty taste perception
KR102262876B1 (ko) 진단 분석에 사용하기 위한 단백질 항원으로서 rep 단백질
EP3086120A1 (en) Diagnosis of a novel autoimmune disease
JP2017038566A (ja) エクソソームの精製用組成物
CN112111015B (zh) PLA2R、C1q、THSD7A融合蛋白及其构建方法、应用
JP2014518624A (ja) ニューログラニン診断キットのためのアッセイ試薬
CN117384287A (zh) 抗bcma单域抗体及其制备方法与应用
CN108779181A (zh) 生产红细胞蛋白质的方法
CN110051836A (zh) 使用膜stim1筛选化合物的方法
JP2010523963A (ja) 診断アッセイ
CN1918299B (zh) 用于生产拴系蛋白的方法
Pacholczyk et al. Epitope and mimotope for an antibody to the Na, K‐ATPase
US20030027147A1 (en) Synaptic activation protein compositions and method
Fiedler et al. Myeloid translocation gene 16b is a dual A-kinase anchoring protein that interacts selectively with plexins in a phospho-regulated manner
DK2077280T3 (en) Carbohydrate Deficient Transferrin (CDT) -specific antibodies, their preparation and use
CN114369154A (zh) 一种n-甲基-d-天冬氨酸受体重组抗原、其制备方法及含有该重组抗原的试剂盒
CN114137231B (zh) 一种血型不规则抗体的检测试剂盒及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination